Roth Capital Initiates Juniper Pharmaceuticals With Buy

Analysts at Roth Capital initiated coverage on

with a Buy rating. The target price for Juniper Pharmaceuticals is set to $15. Juniper Pharmaceuticals shares have gained 9.20 percent over the past 52 weeks, while the S&P 500 index has surged 13.39 percent in the same period. Juniper Pharmaceuticals' shares closed at $7.48 yesterday.